|Bid||0.00 x 3100|
|Ask||0.00 x 4000|
|Day's range||12.01 - 12.25|
|52-week range||8.63 - 14.27|
|Beta (5Y monthly)||1.32|
|PE ratio (TTM)||3.86|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.